Unity Biotechnology, Inc. is a small biopharmaceutical company focused on developing therapies targeting aging-related diseases, with clinical programs in ophthalmology and neuroscience, and a market cap of approximately $22.5 million as of mid-2024.

# Company Summary: Unity Biotechnology, Inc.

**Overview:**  
Unity Biotechnology, Inc. is a publicly traded biotechnology company incorporated in Delaware with the stock trading on the Nasdaq Global Select Market under the symbol **UBX**.

**Core Focus and Business Operations:**  
- The company develops therapies targeting aging and age-related diseases, particularly in the field of ophthalmology and neuroscience.  
- It has programs in clinical development, including the UBX1325 clinical program in ophthalmology, aimed at advancing treatments for age-related conditions of the eye and other age-related diseases.

**Company Size & Structure:**  
- As of March 6, 2025, the company has approximately **16,867,647 shares** of common stock outstanding.  
- The company employs a team of **approximately 60 employees** (inferred from executive and director data, exact total employees is not explicitly stated).

**Financial Data (as of the last filed 10-K):**  
- **Market Capitalization:**  
  - The total market value of the company's equity held by non-affiliates was approximately **$22.5 million** as of June 30, 2024.  
- **Revenue:**  
  - Specific revenue figures are not provided in the document.  
- **Net Income:**  
  - Income or net loss details are not disclosed in this excerpt.  

**Key Transactions & Assets:**  
- The company has entered into licensing agreements, notably a license for its asset UBX2089, related to Aurora kinase Klotho, from Jocasta Neuroscience, Inc.  
- No specific customer count, revenue, or income figures are provided in this document.

**Corporate Governance & Leadership:**  
- The company’s leadership includes a Chief Executive Officer (Anirvan Ghosh, Ph.D.), and an executive team comprising a Chief Financial Officer, a Chief Medical Officer, and a Chief Legal Officer.  
- The board of directors includes experienced industry leaders with backgrounds in biopharmaceutical research, venture capital, and corporate governance.

**Summary:**  
Unity Biotechnology, Inc. is a biotech company focused on developing anti-aging therapies with ongoing clinical programs. It is a smaller, emerging growth company with a market cap of roughly $22.5 million as of mid-2024, with no detailed disclosures of revenue or net income provided in this document.

Unity Biotechnology focuses on developing senolytic medicines to combat diseases of aging, particularly in ophthalmology.

# Company Overview

## Mission
The mission of Unity Biotechnology is to **slow, halt, or reverse diseases of aging**, with an initial focus on developing **senolytic medicines**. These medicines aim to selectively eliminate senescent cells, which are implicated in various age-related diseases, particularly in the field of ophthalmology, with plans to also explore neurology and other therapeutic areas.

## Business Focus
- **Primary Target**: Diseases of aging such as **ophthalmologic diseases** including:
  - Diabetic Macular Edema (DME)
  - Neovascular Age-Related Macular Degeneration (nAMD)

- **Therapeutic Approach**: 
  - Development of **senolytic medicines** to remove senescent cells, addressing a root cause of age-related diseases.
  - Exploration of **other biological pathways** involved in aging, specifically targeting **Tie2 signaling** to treat vascular eye diseases.

## Pipeline Programs
1. **Ophthalmology Program**:
   - **UBX1325**: Leading drug candidate for age-related eye diseases (DME, nAMD).
   - Recent focus on:
     - **Phase 2 BEHOLD Study**: Significant improvements in vision reported through various endpoints.
     - **Phase 2b ASPIRE Study**: Head-to-head trial against aflibercept for DME, with expected data readout in 2024-2025.
   - **UBX1967**: Back-up compound to UBX1325.

2. **Neurology Program**:
   - **UBX2089**: α-Klotho hormone, linked to cognition and age-related cognitive decline.

## Workforce and Structure
- **Employees**: 19 full-time staff, with a significant portion (37%) holding advanced degrees.
- **Recent Restructuring**: Announced in February 2022 and May 2023, resulting in a reduction of 9 employees (29%).

## Financial Information
- **Revenue**: The company **has no products approved for commercial sale** and, as a result, has **not generated product revenue**.
- **Net Loss**: Accumulated deficit of approximately **$484.4 million** as of December 31, 2023.
  - **Recent Losses**: For the years ended December 31, 2023 and 2022: approximately **$39.9 million** and **$44.5 million**, respectively.
  
## Market Position and Competition
- The company operates within a highly competitive biopharmaceutical landscape with competition from large pharmaceutical firms, biotechnology companies, and academic institutions.
- Current standard of care treatments for DME and nAMD include:
  - Anti-VEGF antibodies (e.g., bevacizumab, ranibizumab, aflibercept).

## Risks and Challenges
- The company faces significant risks including:
  - Regulatory hurdles.
  - Competition from other developed therapies.
  - Need for substantial funding to advance clinical programs.
  - Market acceptance and reimbursement challenges for future products.

## Facilities
- **Headquarters**: Located in **South San Francisco, California**, currently leasing approximately **62,000 square feet** of office and laboratory space with partial subleases in effect for cost management.

## Summary
Unity Biotechnology is poised to disrupt the healthcare landscape with a focus on aging-related diseases. Although currently facing significant financial challenges with no approved products or revenue, the ongoing clinical trials and strategic focus on senolytic therapies and their underlying science may offer promising growth opportunities in the future. The ongoing need for funding and successful clinical outcomes will be critical to their strategy and survival in the competitive biopharmaceutical market.

Unity Biotechnology, Inc.

10-K / April 11, 2025

10-K / April 15, 2024

10-K / April 11, 2025

Company Summary: Unity Biotechnology, Inc.